Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium

Archives of Internal Medicine

Volumn 157, Issue 10, 1997, Pages 1132-1136

  Anglim, Anne M ^a   Klym, Beth ^a   Byers, Karin E ^a   Scheld, W Michael ^a   Farr, Barry M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CHLORAMPHENICOL; GENTAMICIN; NITROFURANTOIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; DRUG COST; ENTEROCOCCUS FAECALIS; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; PRACTICE GUIDELINE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; TREATMENT INDICATION;

EID: 0030975771     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.10.1132     Document Type: Article

References (37)

1. Holmberg S, Solomon S, Blake P. Health and economic impact of antimicrobial resistance. Rev Infect Dis. 1987;9:1065-1078.
2. Landry S, Kaiser D, Wenzel R. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia. Am J Infect Control. 1989;17:323-329.
3. Weinstein L, Goldfield M, Chang T-W. Infections occurring during chemotherapy: a study of their frequency, type, and predisposing factors. N Engl J Med. 1954;251:247-255.
4. Gerding D, Larson T, Hughes R, Weiler M, Shanholtzer C, Peterson L. Aminoglycoside resistance and aminoglycoside usage: ten years experience in one hospital. Antimicrob Agents Chemother. 1991;35:1284-1290.
5. Friedland IR, Funk E, Khoosal M, Klugman KP. Increased resistance to amikacin in a neonatal unit following intensive amikacin usage. Antimicrob Agents Chemother. 1992;36:1596-1600.
6. Ballow CH, Schentag JJ. Trends in antibiotic utilization: report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis. 1992; 15(suppl 2):37s-42s.
7. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681-687.
8. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991;163:1279-1285.
9. Piercy EA, Barbaro D, Luby JP, Mackowiak P. Ciprofloxacin for methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1989;33:128-130.
10. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA. 1993;269:598-602.
11. Goldmann DA. Vancomycin-resistant Enterococcus faecium: headline news. Infect Control Hosp Epidemiol. 1992;13:695-699.
12. Cohen ML. Epidemiology of drug resistance: implications for a post-antibiotic era. Science. 1992;257:1050-1055.
13. Murry BE. Can antibiotic resistance be controlled? N Engl J Med. 1994;330: 1229-1230.
14. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis. 1993;16:750-755.
15. Montecalvo M, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, amipicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother. 1994;38:1363-1367.
16. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol. 1992;13:700-705.
17. Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol. 1992;13:195-200.
18. Quintiliani R, Klimek JJ, Nightingale CH. Restriction policies for therapy with combination antibiotics. J Infect Dis. 1986;153:645-647.
19. Dunagan WC, Woodward RS, Medoff G, et al. Antibiotic misuse in patients with positive blood cultures. Am J Med. 1989;87:253-259.
20. Garibaldi RA, Burke J. Surveillance and control of antibiotic use in the hospital. Am J Infect Control. 1991;19:164-170.
21. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep. 1995;44(RR-12):1-13.
22. Edberg SC, Hardalo CJ, Kontnick C, Campbell S. Rapid detection of vancomycin-resistant enterococci. J Clin Microbiol. 1994;32:2182-2184.
23. Facklam RR, Washington JA II. Streptococcus and related catalase-negative gram-positive cocci. In: Balows A, Hausler Jr WJ, Herrman KL, Isenberg HD, Shadomy HJ, eds: Manual of Clinical Microbiology. 5th ed. Washington DC: American Society for Microbiology; 1991:238-257.
24. McGowan JE, Finland M. A study of antimicrobial misuse in a general hospital: effect of requiring justification. J Infect Dis. 1974;130:165-168.
25. Van Der Auwera P, Vandermies A, Grenier P. Emergence of resistant E. faecium in the fecal flora of human volunteers (H) receiving oral vancomycin (V). In: Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 29-October 2, 1991; Chicago, Ill. Abstract 756.
26. Singer MV, Sands KE. Vancomycin control measures at a tertiary care hospital: impact on volume and appropriateness of use. In: Programs and abstracts of the 33rd Annual Meeting of the Infectious Diseases Society of America; September 16-18, 1995; San Francisco, Calif. Abstract 105.
27. McGowan JE. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull N Y Acad Med. 1987;63:253-268.
28. McGowan JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp. 1994;15:478-483.
29. Dunagan WC, Medoff G. Formulary control of antimicrobial usage: what price freedom? Diagn Microbiol Infect Dis. 1993;16:265-274.
30. Oefinger PE, Goldsmith TL, Atkins JT, et al. Modification of antibiotic usage within a tertiary care teaching hospital. In: Programs and abstracts of the 96th General Meeting of the American Society for Microbiology; May 19-23, 1996; New Orleans, La. Poster 31A1.
31. Crowe HM, Quintiliani R. Antibiotic formulary selection. Med Clin North Am. 1995;79:463-476.
32. Batteiger B, Sorensen S, Clark C, et al. Reduction in antibiotic expenditures after implementation of an antimicrobial prescribing improvement program. In: Programs and abstracts of the 34th Meeting of the Infectious Diseases Society of America; September 18-20, 1996; New Orleans, La. Abstract 11.
33. Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetics service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit. 1990;12:427-433.
34. Livornese LL, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med. 1992;117:112-116.
35. Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol. 1994;32:1148-1153.
36. Morris JG, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin establishment of endemicity in a university medical center. Ann Intern Med. 1995;123:251-259.
37. Gordts B, Claeys K, Jannes H, Van Landuyt HW. Are vancomycin resistant enterococci (VRE) normal inhabitants of the G.I. tract of hospitalized patients? In: Programs and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 5-7, 1994; Orlando, Fla. Abstract J151.